RFX7 and lymphoma: It has been identified as a putative major cancer driver mutated in 13 to 15 % of Epstein-Barr Virus-negative Burkitt lymphoma [2, 3], and CRISPR/Cas9-targeting of Rfx7 in a mouse lymphoma model confirmed its function as a tumor suppressor [4].